AIS
FULC icon

Accurate Investment Solutions’s Fulcrum Therapeutics FULC Stock Holding History

Accurate Investment Solutions’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-300
Closed -$4K – 151
2020
Q1 		$4K Buy
+300
New +$4.8K ﹤0.01% 345

Other funds holding FULC

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Accurate Investment Solutions's FULC Position: Q2 2020 in Review

Accurate Investment Solutions sold out of Fulcrum Therapeutics (FULC) in Q2 2020, closing a stake of 300 shares — an estimated $4K sold.

Accurate Investment Solutions first reported a position in FULC in Q1 2020 and held it in 1 quarter. The position peaked at $4K in Q1 2020. 61 funds tracked by Wall St. Rank hold FULC as of Q2 2020.

  • Accurate Investment Solutions reported no remaining Fulcrum Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Accurate Investment Solutions sold 300 Fulcrum Therapeutics shares in Q2 2020, an estimated $4K.
  • Accurate Investment Solutions first reported a position in Fulcrum Therapeutics in Q1 2020 and held it in 1 quarter.
  • Accurate Investment Solutions's Fulcrum Therapeutics position peaked at $4K in Q1 2020.
  • 61 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2020.

Based on Accurate Investment Solutions's 13F filing for Q2 2020.